

UNIVERSITY OF BIRMINGHAM

University of Birmingham
Research at Birmingham

Together towards a common goal

Pentz-Murr, Astrid; Piddock, Laura J V

DOI:

[10.1093/jac/dkz077](https://doi.org/10.1093/jac/dkz077)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Pentz-Murr, A & Piddock, LJV 2019, 'Together towards a common goal: REVIVE, a community of antimicrobial researchers brought together by the Global Antibiotic Research & Development Partnership (GARDP)', *Journal of Antimicrobial Chemotherapy*, vol. 74, no. 7, pp. 1769-1770. <https://doi.org/10.1093/jac/dkz077>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 06/03/2019

This is a pre-copyedited, author-produced version of an article accepted for publication in *Journal of Antimicrobial Chemotherapy* following peer review. The version of record [insert complete citation information here] is available online at: <https://doi.org/10.1093/jac/dkz077>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 **Together towards a common goal – REVIVE, a community of antimicrobial**
2 **researchers, brought together by the Global Antibiotic R&D Partnership**
3 **(GARDP)**

4

5 Astrid Pentz-Murr* and Laura JV Piddock

6 Address: Global Antibiotic R&D Partnership (GARDP), c/o Drugs for Neglected Diseases initiative, 15

7 Chemin Louis-Dunant, 1202 Geneva, Switzerland

8 Telephone number: +41 22 907 76 29

9 *Corresponding author contact email: apentz-murr@dndi.org

10 Main text word count: 667

11 Running title: REVIVE, connecting and supporting the antimicrobial R&D community

12 **Abstract**

13 The Global Antibiotic R&D Partnership (GARDP) has launched a project, REVIVE, to connect and
14 support the antimicrobial R&D community. REVIVE's educational activities include a webinar series
15 and sessions and presentations at key conferences. REVIVE also aims to connect antimicrobial
16 researchers with each other, with current experts in the field and with laureate experts, and to
17 develop a comprehensive repository of relevant resources for the R&D community.

18

19 **Main text**

20 The Global Antibiotic Research & Development Partnership (GARDP; gardp.org) is a not-for-profit
21 research and development organization that addresses global public health needs by developing and
22 delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable
23 access. Initiated by the WHO and the Drugs for Neglected Diseases *initiative* (DNDi), GARDP is an
24 important element of WHO's Global Action Plan on Antimicrobial Resistance that calls for new
25 public-private partnerships to encourage research and development of new antimicrobial agents
26 and diagnostics.

27

28 It has been often discussed that there is a 'discovery void' in the development of antibiotics; many
29 companies have left the field and many researchers changed their field of work or retired. This is a
30 loss to the community with valuable experience and knowledge at risk of being lost forever.

31 Ironically, while today's technology can better connect researchers, working in a research field with
32 a steady turn over and loss of life time experts has left researchers new to antimicrobial R&D
33 isolated. With this in mind, GARDP created REVIVE to support and connect the antimicrobial R&D
34 community, facilitate learning, and share knowledge, and in January 2018, launched the website
35 REVIVE (revive.gardp.org).

36

37 REVIVE's aim is to improve, accelerate, and streamline antimicrobial drug discovery and R&D by
38 connecting researchers directly with established and retired antimicrobial researchers and
39 developers. To preserve their knowledge and to make it accessible to other researchers, REVIVE's
40 expert group comprises those with a track record in antimicrobial discovery, R&D. REVIVE provides
41 those in academia, start-up and biotech companies in the field with access to scientific advice from
42 highly experienced drug developers. Those working on antimicrobials can engage with the REVIVE
43 expert group via the website's 'Talk to an expert' interface (revive.gardp.org/talk-to-an-expert).

44 Thus, REVIVE provides a forum for exchange between early career researchers, drug developers
45 experienced in other disease areas now refocusing their research to address the antimicrobial
46 resistance (AMR) crisis, clinical and non-clinical researchers. To date, 91 experts have committed to
47 support REVIVE and this is continuously expanding. GARDP is happy to consider additional experts.

48

49 REVIVE has a strong educational focus. The REVIVE webinar series was launched in June 2018 and so
50 far, four webinars have been held. In the first webinar, David Shlaes discussed traditional
51 development pathways for antimicrobial drugs (revive.gardp.org/clinical-development-1). In the
52 second, William Hope gave insights on pharmacokinetics and pharmacodynamics of antimicrobials
53 (revive.gardp.org/pk-pd-in-support-of-accelerated-programmes-for-antimicrobial-development).

54 The third webinar was a panel discussion about the development of antibiotics targeting specific
55 pathogens with Ian Friedland, Sumathi Nambiar, Mair Powell, and David Shlaes
56 (<https://revive.gardp.org/clinical-development-2-specific-pathogens/>). In the last webinar of 2018,
57 Claire Sadler answered audience questions following the viewing of her recorded presentation
58 'Making Safety a Part of Drug Design' from the ESCMID/ASM Conference on Drug Development to
59 Meet the Challenge of Antimicrobial Resistance 2018 (<https://revive.gardp.org/making-safety-a-part-of-drug-design/>). All webinar presentations were followed by generous question and answer
60 sessions where the speakers responded to audience questions. More webinars will follow in 2019
61 (revive.gardp.org/category/webinars).

62

63

64 In addition to these virtual events, GARDP is also co-organizing conference sessions with other
65 organisations, including BSAC and CARB-X, at conferences including ECCMID and ASM Microbe. As a
66 not-for-profit organization with a global scope, GARDP makes recordings of their conference
67 sessions available free of charge on REVIVE.

68

69 The latest addition to REVIVE has been the REVIVE Blog which aims to share knowledge and
70 stimulate discussions on topics relevant to AMR. The blog was launched in November 2018 with a
71 post by guest author Lord Jim O'Neill on economic models for antimicrobial drug development
72 (<https://revive.gardp.org/more-than-one-model-to-stimulate-antimicrobial-drug-development/>).

73

74 REVIVE also aims to provide a comprehensive repository of relevant resources for antimicrobial
75 researchers. The focus of these resources is freely available, open-access information. GARDP is
76 working with other organisations to identify resources and welcomes suggestions and requests for
77 resources.

78

79 In summary, REVIVE is a space for the antimicrobial R&D community to connect and exchange
80 information. It is GARDP's vision to grow REVIVE with the community, in collaboration with all
81 participants, from early-career researchers to seasoned experts so as to meet their needs.

82 Therefore, we ask readers to work with GARDP on REVIVE.

83

84

85 **Transparency Declarations**

86 None to declare.